Kimia Biosciences Limited has dispatched its postal ballot notice to shareholders on February 18, 2026, seeking approval for the re-appointment of Managing Director Sameer Goel. The company had earlier approved the postal ballot process following board meetings held on February 14 and February 16, 2026, where it modified the original notice by withdrawing one agenda item.

Postal Ballot Process and Timeline

The postal ballot notice has been dispatched to all eligible shareholders whose email addresses are registered with the company or depositories as of the cut-off date of February 6, 2026. The company is conducting the postal ballot exclusively through electronic voting in compliance with MCA circulars and SEBI regulations.

Managing Director Re-appointment Details

The sole agenda item in the revised postal ballot seeks shareholder approval for the re-appointment of Mr. Sameer Goel (DIN: 00161786) as Managing Director for a five-year term. The board had earlier withdrawn the regularisation of Mr. Kaku Vijaya Shekhar Reddy as Whole Time Director from the postal ballot agenda.

Background and Qualifications

Mr. Sameer Goel, aged 52 years, is a Delhi University Commerce graduate with extensive experience in the Indian API market. As the founder of Kimia Biosciences Limited, he has established the company as a significant player in bulk drugs addressing various high-potential therapeutic segments. He possesses strong capabilities in business development, product development, strategic marketing, and operations management.

E-voting Process and Compliance

Shareholders can cast their votes through NSDL's e-voting platform at www.evoting.nsdl.com . The company has appointed Mr. Maghisuddin, proprietor of M/s M & Company, as the scrutinizer to oversee the e-voting process. The postal ballot notice is available on the company's website at www.kimiabiosciences.com and on BSE's website.

The resolution, if passed by the requisite majority, will be deemed to have been passed on March 21, 2026. The scrutinizer will submit the report within two working days of the conclusion of remote e-voting, and results will be declared and communicated to the stock exchange where the company's shares are listed.

Kimia biosciences Limited has secured a significant patent grant from The Patent Office, Government of India, strengthening its position in the antifungal pharmaceutical segment. The company announced this development through a regulatory filing to BSE Limited on February 10, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Patent Details and Specifications

The patent, officially numbered 579384, covers an "Improved Process for the Preparation of Luliconazole," an important antifungal active pharmaceutical ingredient (API). The patent certificate confirms the grant for a standard term of 20 years, effective from the original filing date.

Strategic Impact on Business Portfolio

The patent grant represents a significant addition to Kimia Biosciences' intellectual property portfolio, particularly in the antifungal API segment. According to the company's regulatory communication, this patent is expected to enhance long-term business prospects by providing exclusive rights to the improved manufacturing process for Luliconazole.

Luliconazole is a topical antifungal medication used to treat various fungal skin infections. The patent covers an improved preparation process, which could potentially offer manufacturing advantages such as enhanced efficiency, better yield, or improved product quality compared to existing methods.

Regulatory Compliance and Documentation

The announcement was made through proper regulatory channels, with Company Secretary and Compliance Officer Pallavi Garg (Membership No. A69848) signing the disclosure document. The filing includes the complete patent certificate as supporting documentation, ensuring full transparency with stakeholders and regulatory authorities.

Patent Maintenance Requirements

The patent certificate specifies that renewal fees for maintaining the patent will be due on January 9, 2024, and annually thereafter on the same date. This ongoing financial commitment will be necessary to preserve the exclusive rights throughout the 20-year patent term.

This patent grant positions Kimia Biosciences Limited to potentially leverage its proprietary process technology in the competitive antifungal API market, providing a foundation for future business development and market expansion opportunities.